Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Hatch/Enzi/Hagan amendment retains the number from last year's bill, but a fight on floor seems possible.
You may also be interested in...
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At Generics Group
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.